veriNOS pharmaceuticals GmbH
Diabetic Retinopathy Services
Ronopterin – treatment to reduce retinal edema and improve patient outcomes. Adequate, pharmacologic control of retinal edema progression in diabetes is still insufficient. More than 50% of patients suffer from impairing side effects and require repetitive injections into the eye.
Most popular related searches
Ronopterin offers a potential solution to address the unmet medical need as Ronopterin decreases uncontrolled cell activation and edema formation by inhibiting the release of the cell damaging radicals and glutamate.
- Mechanistically similar edema formation as in TBI
- Ronopterin inhibits retinal spreading depression, preventing progressive tissue injury
- Glutamate induces progressive retinal damage
- Retinal inflammation, hypoxia, ischemia increase iNOS expression and radical formation
- Aiming to reduce retinal edema as a superior alternative to steroids and to decrease side effects of steroids
Worldwide approx. 220 million patients suffer from diabetic retinopathy with 45 million patients experiencing impaired vision.
Incidence in diabetic retinopathy is projected to increase by 50% within the next 10 years.
Current treatments are insufficient with high incidence of recurrent edema and progressive loss in vision requiring repetitive injections in the eye.
In more than 50% of patient’s synthetic steroids fail to reduce retinal edema which may promote recurrence of aggravated edema formation and vessel proliferation.
The high economic burden and undermet medical need account for a market potential of 17 bn USD annually by 2030.